Cite
Towards sustainability and affordability of expensive cell and gene therapies? Applying a cost-based pricing model to estimate prices for Libmeldy and Zolgensma.
MLA
Thielen, Frederick W., et al. “Towards Sustainability and Affordability of Expensive Cell and Gene Therapies? Applying a Cost-Based Pricing Model to Estimate Prices for Libmeldy and Zolgensma.” Cytotherapy (Elsevier Inc.), vol. 24, no. 12, Dec. 2022, pp. 1245–58. EBSCOhost, https://doi.org/10.1016/j.jcyt.2022.09.002.
APA
Thielen, F. W., Heine, R. J. S. D., Berg, S. van den, Ham, R. M. T. ten, & Groot, C. A. U. (2022). Towards sustainability and affordability of expensive cell and gene therapies? Applying a cost-based pricing model to estimate prices for Libmeldy and Zolgensma. Cytotherapy (Elsevier Inc.), 24(12), 1245–1258. https://doi.org/10.1016/j.jcyt.2022.09.002
Chicago
Thielen, Frederick W., Renaud J.S.D. Heine, Sibren van den Berg, Renske M. T. ten Ham, and Carin A. Uyl-de Groot. 2022. “Towards Sustainability and Affordability of Expensive Cell and Gene Therapies? Applying a Cost-Based Pricing Model to Estimate Prices for Libmeldy and Zolgensma.” Cytotherapy (Elsevier Inc.) 24 (12): 1245–58. doi:10.1016/j.jcyt.2022.09.002.